NIVOLUMAB PLUS IPILIMUMAB IS WELL TOLERATED AND ACTIVE IN NSCLC

[Anonymous]

CANCER DISCOVERY, 2017; 7 (2): 124

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索